Find out more about what we’ve been up to in our latest newsletter. There are updates on our COVID-19 research, including our collaboration with ISARIC, which has assembled the world’s largest global database on COVID-19 clinical data.

Drug-resistant malaria is now a critical public health emergency on a global scale. In a new editorial a diverse group of malaria researchers, including WWARN senior scientists, have highlighted that the artemisinin confirmed recently in Rwanda and Uganda is likely just the ‘tip of the spear’, with ...

Hear from our Director, Professor Philippe Guérin, at the Geneva Health Forum’s plenary roundtable on 4 May on “Data sharing in the time of COVID-19: What works and what we need”.

The Indian government’s Union Cabinet, chaired by Prime Minister Shri Narendra Modi, has approved a Memorandum of Understanding (MoU) between the Indian Council of Medical Research (ICMR) and the Infectious Diseases Data Observatory (IDDO), based at the University of Oxford.

WWARN researchers have been assessing the recommended minimum follow-up period in capturing polymerase chain reaction (PCR)-confirmed recrudescence following treatment with fixed-dose artemisinin combination therapies (ACTs) for patients with uncomplicated Plasmodium falciparum malaria. 

A key expert invited to speak at WHO’s recent Health Data Governance Summit was Cherif Mahamoud Sama, a recipient of TDR’s Clinical Research and Development Fellowship (CRDF).

Last year, the Indian Council for Medical Research (ICMR) National Institute of Malaria Research (NIMR) and IDDO began collaborating on a joint capacity building venture to train young researchers across three infectious diseases.

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published today in BMC Medicine. 

IDDO/WWARN and University of Cape Town (UCT) TDR post-doctoral fellow Dr Daniel Yilma presented his latest malaria research at the recent workshop in Ethiopia.

KINSHASA / NAIROBI / GENEVA – 28 February 2022 – The ANTICOV platform clinical trial, launched in September 2020 in 13 African countries to identify treatments for mild and moderate cases of COVID-19, has stopped recruiting patients into one of its treatment arms, the drug combination nitazoxanide a...

Early career researchers are invited to apply for the RSTMH 2022 grant programme to help fund a one-year project on any topic related to tropical medicine and global health.

KINSHASA / NAIROBI / GENEVA – 8 February 2022 – The ANTICOV platform clinical trial has started the recruitment of participants to test a new promising drug combination, fluoxetine and budesonide, as an early treatment for people affected with mild-to-moderate COVID-19.

WWARN experts recently spoke to Undark magazine about the emerging signs of antimalarial drug resistance in sub-Saharan Africa and what that means for the region. 

A new study has highlighted the need for more rapid dissemination of molecular marker data to monitor artemisinin resistance.

Professor Paul Newton was announced new Distinguished International Fellow at the ASTMH Annual Meeting Awards Ceremony on the 17th November. This distinction formally recognises individuals who have made eminent contributions to a particular aspect of tropical medicine or hygiene.

A new, extensive systematic review has identified significant research gaps in the treatment of scrub typhus which could be improved by developing a database for individual participant data (IPD) to enable more detailed analyses to address important knowledge gaps such as the optimum dosing for chil...

IDDO has partnered with Vivli today, listing its COVID-19 studies on the platform to boost its reach across the global research community and increase both the speed of access and re-use of data.

A series of papers which reviewed portable devices to detect poor quality medicines has concluded major gaps in scientific evidence remain a key barrier for regulators to implement surveillance systems using such devices.

A new study suggests there are important but neglected issues with substandard and falsified (SF*) medicines and medical products used to prevent and treat cardiovascular diseases.

Two new Study Groups, a collaboration between IDDO and the global visceral leishmaniasis (VL) research community, have been formed to answer specific research questions about treatments. They will undertake individual patient data meta-analyses using datasets from multiple studies, across sub-popula...